Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.6952W HIGH $5.17
Volume
2.51 M
Value Traded
7.17 M
Short % Float
35.53%
+5.69%Week
-7.06%1 Month
-19.39%3 Month
+14.49%6 Month
-90.41%5 Year
-86.62%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
388.76 M
EPS (TTM)
-0.82
P/E Ratio
-
Ent. Value
88.31 M
Total Shares
123.03 M
Float Shares
113.12 M
Insiders
8.05%
Institutions
96.54%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
CCCC Catalyst Timeline
Dated clinical, regulatory and corporate events for C4 Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for C4 Therapeutics, Inc.
278Total events
10Upcoming
32Tier-1 (high impact)
2020 to 2028Coverage
Upcoming catalysts 2
Event history 50
●Poster PresentationcemsidomidePresentation
Poster presentation of biomarker data from Phase 1 trial of cemsidomide with dexamethasone at IMS Annual Meeting
relapsed/refractory multiple myelomasource ↗
▲Biomarker DatacemsidomideClinical Data
Biomarker data from Phase 1 trial of cemsidomide with dexamethasone showing T-cell activation and NK cell reprogramming
relapsed/refractory multiple myelomasource ↗
▲Dose Finding UpdatecemsidomideTrial
75 µg cemsidomide dose level declared safe; Phase 1b trial advancing to 100 µg escalation and 75 µg expansion cohorts
relapsed/refractory multiple myelomasource ↗
▲Safety Data UpdatecemsidomideClinical Data
Safety data review committee declares 75 µg cemsidomide dose level safe in Phase 1b trial with elranatamab
relapsed/refractory multiple myelomasource ↗
▲Safety Data UpdatecemsidomideClinical Data
Safety data review committee declared 75 µg cemsidomide dose level safe in Phase 1b trial with elranatamab
relapsed/refractory multiple myelomasource ↗
▲Dose Finding UpdatecemsidomideTrial
Phase 1b trial advancing to dose escalation safety cohort at 100 µg and expansion cohort at 75 µg
relapsed/refractory multiple myelomasource ↗
▲Biomarker DatacemsidomideClinical Data
Preliminary biomarker data from first two patients in Phase 1b trial of cemsidomide with elranatamab
relapsed/refractory multiple myelomasource ↗
◆Poster PresentationcemsidomidePresentation
Poster presentation of updated Phase 1 data at EHA Congress
relapsed/refractory multiple myelomasource ↗
◆Poster PresentationcemsidomidePresentation
Trial-in-progress poster for MOMENTUM trial at ASCO 2026
relapsed/refractory multiple myelomasource ↗
▼Program DiscontinuationCFT8919DiscontinuedCorporate
Decision to not advance CFT8919 into next phase outside Greater China
EGFR mutated non-small cell lung cancersource ↗
▲Partnership / LicenseCorporate
C4 Therapeutics enters new collaboration with Roche to develop degrader-antibody conjugates (DACs) for two oncology targets, with option for third
oncologysource ↗
◆Trial InitiationcemsidomideTrial
Phase 1b trial of cemsidomide + elranatamab initiation on track for Q2 2026
relapsed/refractory multiple myelomasource ↗
◆Timing GuidancecemsidomidePresentation
Plans to evaluate cemsidomide in other combinations to be shared in mid-2026
multiple myelomasource ↗
▲Partnership / LicenseCorporate
New collaboration agreement with Roche for degrader-antibody conjugates
cancersource ↗
▲First Patient DosedcemsidomideTrial
First patient dosed in Phase 1b trial of cemsidomide + elranatamab
relapsed/refractory multiple myelomasource ↗
▲Enrollment CompletecemsidomideTrial
Phase 1 trial enrollment completed
relapsed/refractory multiple myelomasource ↗
◆Oral PresentationPresentation
C4T management to participate in two upcoming March conferences
▲First Patient DosedcemsidomideTrial
First patient dosed in Phase 1b trial of cemsidomide + dexamethasone + elranatamab
multiple myelomasource ↗
▲First Patient DosedcemsidomideTrial
First patient dosed in Phase 2 MOMENTUM trial of cemsidomide for multiple myeloma in fourth line or later
Relapsed Refractory Multiple Myelomasource ↗
▲First Patient DosedcemsidomideTrial
First patient dosed in Phase 2 MOMENTUM trial of cemsidomide + dexamethasone
relapsed/refractory multiple myelomasource ↗
◆Oral PresentationPresentation
C4T management fireside chat at Guggenheim Emerging Outlook: Biotech Summit 2026
▲First Patient DosedcemsidomideTrial
First patient dosed in Phase 2 MOMENTUM trial
multiple myelomasource ↗
◆Trial InitiationcemsidomideTrial
Initiate next phase of clinical development for cemsidomide in multiple myeloma
relapsed/refractory multiple myelomasource ↗
◆First Patient DosedcemsidomideTrial
Align with FDA on recommended Phase 2 dose based on Phase 1 MM data
multiple myelomasource ↗
▲Topline ReadoutcemsidomideClinical Data
Phase 1 data showed 53% overall response rate at highest dose level (100 µg)
relapsed/refractory multiple myelomasource ↗
▲Partnership / LicensecemsidomideCorporate
Entered into clinical trial collaboration and supply agreement with Pfizer to evaluate cemsidomide in combination with elranatamab
relapsed/refractory multiple myelomasource ↗
◆Poster PresentationcemsidomidePresentation
Poster on population PK and exposure-response relationships in MM and NHL at ACoP 2025
multiple myelomasource ↗
▼Equity OfferingCorporate
Pricing of $125 million underwritten offering of common stock and warrants
▲Partnership / LicensecemsidomideCorporate
Clinical trial collaboration supply agreement with Pfizer for elranatamab
relapsed/refractory multiple myelomasource ↗
◆Oral PresentationcemsidomidePresentation
Complete cemsidomide Phase 1 dose escalation in NHL and present data in Q4 2025
non-Hodgkin's lymphomasource ↗
◆Oral PresentationcemsidomidePresentation
Oral presentation of updated Phase 1 data for cemsidomide at IMS Annual Meeting
multiple myelomasource ↗
▲Enrollment CompletecemsidomideTrial
Phase 1 enrollment completed
relapsed/refractory multiple myelomasource ↗
◆Oral PresentationcemsidomidePresentation
Investor call to discuss cemsidomide MM data in conjunction with IMS presentation
multiple myelomasource ↗
▲Enrollment CompletecemsidomideTrial
Completed enrollment and dose escalation for Phase 1 trial of cemsidomide in MM
multiple myelomasource ↗
▲Enrollment CompletecemsidomideTrial
Enrollment completed in Phase 1 trial of cemsidomide + dexamethasone
relapsed/refractory multiple myelomasource ↗
▲Enrollment CompletecemsidomideTrial
Completed enrollment and dose escalation for Phase 1 trial of cemsidomide in MM and NHL
multiple myelomasource ↗
Past FDA Catalysts and PDUFA Decisions
How CCCC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-25 | cemsidomide | Phase 1 data presentation | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C43 / 100
Pipeline Score
$401M
Pipeline Value
Fair Value
Valuation Signal
2
Drugs Scored
1.0x
rNPV / MCap
Top 31%
Micro Cap(rank 205 of 660)
Percentile Rank
C4 Therapeutics, Inc. carries a moderate pipeline score (43/100), with $1.0B risk-adjusted pipeline value, led by cemsidomide in Multiple Myeloma (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| cemsidomide Small moleculeNCT04756726 | Multiple Myeloma | Phase 2 | ACTIVE NOT_RECRUITING | 384 | Dec 31, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every CCCC program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| cemsidomide | relapsed/refractory multiple myeloma | Phase 1 | 2026-09-25 | 62 heavily pre-treated RRMM patients; 75 µg and 100 µg; elevated HLA-DR; PD-1, TIM-3 and LAG3 expressionRead More | C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual MeetingRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Adams KendraOfficer (Chief Financial Officer) | Option | 6,250 385,098 held | $0.00 | 09/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CCCC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 0.3 % (50 %) | 37.36 M | 8.00 M |
CCCC Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CCCC ranks across every disease it competes in
Competitive Position is a premium feature
See how CCCC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCCCC News
CCCCC4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting
C4 Therapeutics presented new biomarker data from its Phase 1 trial of cemsidomide combined with dexamethasone and the Phase 1b trial with elranatamab at the IMS Annual Meeting. The data indicate significant T-cell activation and safety in initial cohorts. The trials aim to establish cemsidomide as a key treatment option for relapsed/refractory multiple myeloma, with further data expected in mid-2027.
Read more →CCCCC4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting
C4 Therapeutics announced the presentation of new biomarker data on cemsidomide's immunomodulatory effects in combination with dexamethasone at the 23rd IMS Annual Meeting. This data, derived from their Phase 1 trial for relapsed/refractory multiple myeloma, highlights the immune effects on T cells and NK cells. The meeting is scheduled for September 23-26, 2026, in Glasgow, Scotland.
Read more →CCCC▲ +6.9%on this news· ran to +17% by day 3
C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
C4 Therapeutics reported its second quarter 2026 financial results, highlighting the ongoing Phase 2 MOMENTUM trial and a Phase 1b trial of Cemsidomide in combination with Elranatamab. Both trials are on schedule to provide clinical data readouts in 2027. Additionally, promising Phase 1 data was presented at the European Hematology Association 2026 Congress, supporting Cemsidomide's potential as a leading treatment option.
Read more →CCCC▲ +6.9%on this news· ran to +17% by day 3shared move
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
C4 Therapeutics announced the approval of a non-qualified stock option grant for 162,880 shares to a new employee, as part of an inducement for their employment. This grant, effective August 10, 2026, will vest over four years, with a portion vesting annually. This move is in compliance with Nasdaq Listing Rule 5635(c)(4), reflecting the company's commitment to growth and innovation.
Read more →CCCCC4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population
C4 Therapeutics presented promising Phase 1 data for cemsidomide at the EHA 2026 Congress, showing a 53% overall response rate among heavily pretreated multiple myeloma patients. The drug was well tolerated, with minimal adverse effects. The findings support cemsidomide's potential as a foundational therapy in treating relapsed/refractory multiple myeloma, with evidence of deepening responses over time.
Read more →CCCC▲ +5.5%on this news
C4 Therapeutics to Participate in Upcoming Conferences
C4 Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in several upcoming conferences, including the TD Cowen 7th Annual Oncology Innovation Summit and the Jefferies Global Healthcare Conference. These events will feature management in virtual fireside chats and 1x1 meetings, showcasing the company's commitment to advancing targeted protein degradation science. Live webcasts will be available on their website.
Read more →CCCCC4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
C4 Therapeutics reported its first quarter 2026 financial results, highlighting significant advancements in its clinical trials for cemsidomide, a potential treatment for multiple myeloma. The company initiated two new trials and expanded its collaboration with Roche. Despite a decrease in revenue, C4T maintains a strong financial position to support ongoing development.
Read more →CCCCC4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
C4 Therapeutics has entered a new collaboration agreement with Roche to develop degrader-antibody conjugates (DACs) targeting two oncology indications. The partnership will leverage C4T's proprietary TORPEDO platform and Roche's expertise in antibody-drug conjugation. C4T will receive a $20 million upfront payment and could earn over $1 billion in milestone payments. This collaboration aims to enhance cancer treatment options.
Read more →CCCC▲ +7.6%on this news
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma
C4 Therapeutics has announced the dosing of the first patient in its Phase 1b trial for cemsidomide, an oral IKZF1/3 degrader, in combination with elranatamab for treating relapsed/refractory multiple myeloma. The trial aims to evaluate the safety, tolerability, and preliminary efficacy of this combination therapy. C4T anticipates data from the trial by mid-2027, which is part of a broader strategy to support cemsidomide's use across multiple treatment lines.
Read more →CCCCC4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
C4 Therapeutics reported its financial results for 2025, highlighting advancements in its lead candidate, cemsidomide, which is progressing into later-stage clinical trials for multiple myeloma. The company also announced a strong cash position, enabling operations through 2028. Despite a significant net loss, the company remains optimistic about its drug development pipeline and potential market impact.
Read more →CCCC▲ +6.5%on this news· ran to +29% by day 3shared move
C4 Therapeutics to Participate in Upcoming March Conferences
C4 Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in two upcoming March conferences. The live webcasts will be accessible on the company's website, with archived replays available for 90 days post-event. C4T focuses on targeted protein degradation to develop new medicines aimed at difficult-to-treat diseases.
Read more →CCCC▲ +6.5%on this news· ran to +29% by day 3shared move
C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma
C4 Therapeutics has initiated the Phase 2 MOMENTUM trial, dosing the first patient with cemsidomide combined with dexamethasone for relapsed/refractory multiple myeloma. This trial aims to evaluate the drug's efficacy and safety, building on positive Phase 1 results. The company is also preparing for a Phase 1b trial with cemsidomide and elranatamab.
Read more →CCCCC4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - February 9, 2026
C4 Therapeutics announced the approval of a non-qualified stock option grant for 162,880 shares to a new employee, as part of an Inducement Grant under Nasdaq Listing Rule 5635(c)(4). This grant, effective February 9, 2026, will vest over four years, promoting long-term employment. C4T continues to advance its targeted protein degradation initiatives.
Read more →CCCC▼ -6%on this news
C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
C4 Therapeutics will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026, scheduled for February 11-12 in New York. The company's management will engage in a fireside chat, which will be available via live webcast. This event emphasizes C4T's commitment to advancing targeted protein degradation science.
Read more →CCCCC4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - January 26, 2026
C4 Therapeutics announced the approval of an Inducement Grant for a new employee, consisting of non-qualified stock options for 85,480 shares. This grant, made in accordance with Nasdaq Listing Rule 5635(c)(4), will vest over four years, incentivizing the new hire's continued employment. The exercise price is set at the closing stock price on the grant date.
Read more →CCCCC4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways
C4 Therapeutics has outlined strategic milestones aimed at advancing cemsidomide, an investigational drug for multiple myeloma, with trials set to initiate in 2026. The company is also focusing on novel targets in inflammation and neuro-degenerative diseases. Their financial stability extends through 2028, supporting ongoing development efforts.
Read more →CCCCC4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
C4 Therapeutics reported its Q3 2025 financial results, highlighting a successful equity offering that raised $125 million, extending its financial runway to 2028. The company is advancing its lead candidate, cemsidomide, which demonstrated a 53% overall response rate in Phase 1 trials for multiple myeloma. C4T plans to initiate the registrational Phase 2 MOMENTUM trial in early 2026.
Read more →CCCC▲ +11.7%on this news
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
C4 Therapeutics has announced a $125 million underwritten offering to fund the next phase of its cemsidomide development for multiple myeloma. This includes a registrational Phase 2 trial in combination with dexamethasone and a Phase 1b trial with elranatamab. The offering is expected to close on October 17, 2025, subject to customary conditions.
Read more →About C4 Therapeutics, Inc.
Headquarters490 ARSENAL WAY, WATERTOWN, MA, 02472
BIOPHARMAWATCH ELITE PLUS
Trade the next CCCC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime